Pharmacokinetics of prophylactic micafungin in very-low-birth-weight infants

Pediatric Infectious Disease Journal

Volumn 28, Issue 9, 2009, Pages 840-842

  Kawada, Mayumi ^a   Fukuoka, Noriyasu ^b   Kondo, Masatoshi ^c   Okazaki, Kaoru ^c   Kusaka, Takashi ^a   Kawada, Kou ^a   Itoh, Susumu ^a,b  

^a KAGAWA UNIVERSITY   (Japan)

^b KAGAWA UNIVERSITY HOSPITAL   (Japan)

^c Tokyo Metropolitan Hachioji Children's Hospital   (Japan)

Author keywords

Effect and safety; Micafungin; Pharmacokinetics; Prophylactic use; Very low birth weight infants

Indexed keywords

MICAFUNGIN;

ABSENCE OF SIDE EFFECTS; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; HUMAN; INFANT; INFECTION PREVENTION; MYCOSIS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; TREATMENT DURATION; VERY LOW BIRTH WEIGHT;

EID: 70249103527     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181a0cfd1     Document Type: Article

References (16)

1. Stoll BJ, Gordon T, Korones SB, et al. Late-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Developmental Neonatal Research Network. J Pediatr. 1996;129: 63-71. (Pubitemid 26277248)
2. Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics. 2002;110:285-291.
3. Kaufman D, Fairchild KD. Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants. Clin Microbiol Rev. 2004;17:638-680.
4. Kaufman D, Boyle R, Hazen KC, et al. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med. 2001;345:1660-1666.
5. Manzoni P, Stolfi I, Pugni L, et al. A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N Engl J Med. 2007;356: 2483-2495.
6. Fanaroff AA. Fluconazole for the prevention of fungal infections: get ready, get set, caution. Pediatrics. 2006;117:214-215.
7. Kohno S, Yamaguchi H. Overview of micafungin (MCFG). Jpn J Che-mother. 2002;50:1-7.
8. Warn PA, Sharp A, Morrissey G, et al. In vivo activity of micafungin in apersistently neutropenic murine model of disseminated infection caused by Candida tropicalis. J Antimicrob Chemother. 2002;50:1071-1074.
9. Heresi GP, Gerstmann DR, Reed MD, et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J. 2006;25:1110-1115.
10. Yamato Y, Kaneko H, Tanimoto K, et al. Simultaneous determination of antifungal drug, micafungin, and its two active metabolites in human plasma using high-performance liquid chromatography with fluorescence detection. Jpn J Chemother. 2002;50:68-73.
11. Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability, and pharma-cokinetics of micafungin (FK463) in febrile neutropenic pediatric patients. Anitomicrob Agents Chemother. 2005;49:3317-3324.
12. Azuma J, Nakamura K, Kagayama A, et al. Phase I study of micafungin. Jpn J Chemother. 2002;50(suppl 1):104-147.
13. Azuma J, Nakamura K, Kagayama A, et al. Pharmacokinetic study of micafungin. Jpn J Chemother. 2002;50(suppl 1):155-184.
14. Heimez J, Cagnoni P, Simpson D, et al. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob Agents Chemother. 2005;49:1331-1336.
15. Ikeda F, Otomo K, Nakai T, et al. In vitro activity of a new lipopeptide antifungal agent, micafungin against a variety of clinically important fungi. Jpn J Chemother. 2002;50(suppl 1):8-18.
16. Kaneko H, Yamamoto Y, Hashimoto T, et al. Drug interactions of micaf-ungin in vitro. Jpn J Chemother. 2002;50(suppl 1):94-103